Cargando…
Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide
BACKGROUND: Teriflunomide, a once-daily oral immunomodulator approved for treatment of relapsing-remitting multiple sclerosis, is eliminated slowly from plasma. If necessary to rapidly lower plasma concentrations of teriflunomide, an accelerated elimination procedure using cholestyramine or activate...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Therapeutic Drug Monitoring
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949010/ https://www.ncbi.nlm.nih.gov/pubmed/27015245 http://dx.doi.org/10.1097/FTD.0000000000000302 |
_version_ | 1782443365656166400 |
---|---|
author | Filali-Ansary, Aziz Lunven, Catherine Turpault, Sandrine Beyer, Yann-Joel O'Brien, Amy Delfolie, Astrid Boyanova, Neli Sanderink, Ger-Jan Baldinetti, Francesca |
author_facet | Filali-Ansary, Aziz Lunven, Catherine Turpault, Sandrine Beyer, Yann-Joel O'Brien, Amy Delfolie, Astrid Boyanova, Neli Sanderink, Ger-Jan Baldinetti, Francesca |
author_sort | Filali-Ansary, Aziz |
collection | PubMed |
description | BACKGROUND: Teriflunomide, a once-daily oral immunomodulator approved for treatment of relapsing-remitting multiple sclerosis, is eliminated slowly from plasma. If necessary to rapidly lower plasma concentrations of teriflunomide, an accelerated elimination procedure using cholestyramine or activated charcoal may be used. The current bioanalytical assay for determination of plasma teriflunomide concentration requires laboratory facilities for blood centrifugation and plasma storage. An alternative method, with potential for greater convenience, is dried blood spot (DBS) methodology. Analytical and clinical validations are required to switch from plasma to DBS (finger-prick sampling) methodology. METHODS: Using blood samples from healthy subjects, an LC-MS/MS assay method for quantification of teriflunomide in DBS over a range of 0.01–10 mcg/mL was developed and validated for specificity, selectivity, accuracy, precision, reproducibility, and stability. Results were compared with those from the current plasma assay for determination of plasma teriflunomide concentration. RESULTS: Method was specific and selective relative to endogenous compounds, with process efficiency ∼88%, and no matrix effect. Inaccuracy and imprecision for intraday and interday analyses were <15% at all concentrations tested. Quantification of teriflunomide in DBS assay was not affected by blood deposit volume and punch position within spot, and hematocrit level had a limited but acceptable effect on measurement accuracy. Teriflunomide was stable for at least 4 months at room temperature, and for at least 24 hours at 37°C with and without 95% relative humidity, to cover sampling, drying, and shipment conditions in the field. The correlation between DBS and plasma concentrations (R(2) = 0.97), with an average blood to plasma ratio of 0.59, was concentration independent and constant over time. CONCLUSIONS: DBS sampling is a simple and practical method for monitoring teriflunomide concentrations. |
format | Online Article Text |
id | pubmed-4949010 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Therapeutic Drug Monitoring |
record_format | MEDLINE/PubMed |
spelling | pubmed-49490102016-08-03 Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide Filali-Ansary, Aziz Lunven, Catherine Turpault, Sandrine Beyer, Yann-Joel O'Brien, Amy Delfolie, Astrid Boyanova, Neli Sanderink, Ger-Jan Baldinetti, Francesca Ther Drug Monit Original Article BACKGROUND: Teriflunomide, a once-daily oral immunomodulator approved for treatment of relapsing-remitting multiple sclerosis, is eliminated slowly from plasma. If necessary to rapidly lower plasma concentrations of teriflunomide, an accelerated elimination procedure using cholestyramine or activated charcoal may be used. The current bioanalytical assay for determination of plasma teriflunomide concentration requires laboratory facilities for blood centrifugation and plasma storage. An alternative method, with potential for greater convenience, is dried blood spot (DBS) methodology. Analytical and clinical validations are required to switch from plasma to DBS (finger-prick sampling) methodology. METHODS: Using blood samples from healthy subjects, an LC-MS/MS assay method for quantification of teriflunomide in DBS over a range of 0.01–10 mcg/mL was developed and validated for specificity, selectivity, accuracy, precision, reproducibility, and stability. Results were compared with those from the current plasma assay for determination of plasma teriflunomide concentration. RESULTS: Method was specific and selective relative to endogenous compounds, with process efficiency ∼88%, and no matrix effect. Inaccuracy and imprecision for intraday and interday analyses were <15% at all concentrations tested. Quantification of teriflunomide in DBS assay was not affected by blood deposit volume and punch position within spot, and hematocrit level had a limited but acceptable effect on measurement accuracy. Teriflunomide was stable for at least 4 months at room temperature, and for at least 24 hours at 37°C with and without 95% relative humidity, to cover sampling, drying, and shipment conditions in the field. The correlation between DBS and plasma concentrations (R(2) = 0.97), with an average blood to plasma ratio of 0.59, was concentration independent and constant over time. CONCLUSIONS: DBS sampling is a simple and practical method for monitoring teriflunomide concentrations. Therapeutic Drug Monitoring 2016-08 2016-07-25 /pmc/articles/PMC4949010/ /pubmed/27015245 http://dx.doi.org/10.1097/FTD.0000000000000302 Text en Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially. |
spellingShingle | Original Article Filali-Ansary, Aziz Lunven, Catherine Turpault, Sandrine Beyer, Yann-Joel O'Brien, Amy Delfolie, Astrid Boyanova, Neli Sanderink, Ger-Jan Baldinetti, Francesca Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide |
title | Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide |
title_full | Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide |
title_fullStr | Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide |
title_full_unstemmed | Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide |
title_short | Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide |
title_sort | dried blood spot methodology in combination with liquid chromatography/tandem mass spectrometry facilitates the monitoring of teriflunomide |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949010/ https://www.ncbi.nlm.nih.gov/pubmed/27015245 http://dx.doi.org/10.1097/FTD.0000000000000302 |
work_keys_str_mv | AT filaliansaryaziz driedbloodspotmethodologyincombinationwithliquidchromatographytandemmassspectrometryfacilitatesthemonitoringofteriflunomide AT lunvencatherine driedbloodspotmethodologyincombinationwithliquidchromatographytandemmassspectrometryfacilitatesthemonitoringofteriflunomide AT turpaultsandrine driedbloodspotmethodologyincombinationwithliquidchromatographytandemmassspectrometryfacilitatesthemonitoringofteriflunomide AT beyeryannjoel driedbloodspotmethodologyincombinationwithliquidchromatographytandemmassspectrometryfacilitatesthemonitoringofteriflunomide AT obrienamy driedbloodspotmethodologyincombinationwithliquidchromatographytandemmassspectrometryfacilitatesthemonitoringofteriflunomide AT delfolieastrid driedbloodspotmethodologyincombinationwithliquidchromatographytandemmassspectrometryfacilitatesthemonitoringofteriflunomide AT boyanovaneli driedbloodspotmethodologyincombinationwithliquidchromatographytandemmassspectrometryfacilitatesthemonitoringofteriflunomide AT sanderinkgerjan driedbloodspotmethodologyincombinationwithliquidchromatographytandemmassspectrometryfacilitatesthemonitoringofteriflunomide AT baldinettifrancesca driedbloodspotmethodologyincombinationwithliquidchromatographytandemmassspectrometryfacilitatesthemonitoringofteriflunomide |